DK2807188T3 - Humaniserede antistoffer, der genkender alpha-synuclein - Google Patents
Humaniserede antistoffer, der genkender alpha-synuclein Download PDFInfo
- Publication number
- DK2807188T3 DK2807188T3 DK13740871.2T DK13740871T DK2807188T3 DK 2807188 T3 DK2807188 T3 DK 2807188T3 DK 13740871 T DK13740871 T DK 13740871T DK 2807188 T3 DK2807188 T3 DK 2807188T3
- Authority
- DK
- Denmark
- Prior art keywords
- humanized antibodies
- antibodies recognizing
- alpha synuclein
- recognizing alpha
- synuclein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591835P | 2012-01-27 | 2012-01-27 | |
US201261711207P | 2012-10-08 | 2012-10-08 | |
PCT/US2013/023307 WO2013112945A1 (en) | 2012-01-27 | 2013-01-25 | Humanized antibodies that recognize alpha-synuclein |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2807188T3 true DK2807188T3 (da) | 2019-10-07 |
Family
ID=48873980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13740871.2T DK2807188T3 (da) | 2012-01-27 | 2013-01-25 | Humaniserede antistoffer, der genkender alpha-synuclein |
Country Status (23)
Country | Link |
---|---|
US (7) | US8790644B2 (da) |
EP (1) | EP2807188B1 (da) |
JP (2) | JP6342333B2 (da) |
KR (2) | KR102246217B1 (da) |
CN (2) | CN104619724B (da) |
AU (1) | AU2013211874B2 (da) |
BR (1) | BR112014018561A8 (da) |
CA (1) | CA2863953A1 (da) |
CL (1) | CL2014001984A1 (da) |
DK (1) | DK2807188T3 (da) |
ES (1) | ES2749457T3 (da) |
HK (1) | HK1204791A1 (da) |
IL (2) | IL233829B (da) |
IN (1) | IN2014DN07149A (da) |
MX (2) | MX360778B (da) |
MY (1) | MY171140A (da) |
NZ (1) | NZ629296A (da) |
PH (1) | PH12014501685A1 (da) |
RU (1) | RU2642262C2 (da) |
SG (1) | SG11201404321YA (da) |
UA (1) | UA115439C2 (da) |
WO (1) | WO2013112945A1 (da) |
ZA (1) | ZA201406227B (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
EP2807188B1 (en) | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
SG10201800982QA (en) * | 2013-07-05 | 2018-03-28 | Genmab As | Humanized or chimeric cd3 antibodies |
SI3071597T1 (sl) * | 2013-11-21 | 2020-11-30 | F. Hoffmann-La Roche Ag | Anti alfa-sinukleinska protitelesa in postopki uporabe |
JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック, インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
CN106568969B (zh) * | 2016-10-19 | 2017-09-26 | 首都医科大学 | 一种丝氨酸129位磷酸化alpha‑突触核蛋白聚集体的ELISA检测方法 |
JP2020501132A (ja) * | 2016-12-02 | 2020-01-16 | プロセナ バイオサイエンシーズ リミテッド | α−シヌクレインの二次構造プロファイルを検出する赤外線アッセイ |
WO2018151821A1 (en) * | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
EP3406632A1 (en) | 2017-05-23 | 2018-11-28 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Ligands binding to prion protein for use in the treatment of synucleinopathies |
WO2019117684A1 (ko) * | 2017-12-14 | 2019-06-20 | 에이비엘바이오 주식회사 | a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도 |
GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
US11505610B2 (en) | 2018-04-06 | 2022-11-22 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
US20220018851A1 (en) | 2018-08-09 | 2022-01-20 | Hoffmann-La Roche Inc. | Determination of parkinson's disease |
MX2021004454A (es) * | 2018-10-19 | 2021-07-07 | Janssen Vaccines & Prevention Bv | Anticuerpos anti-sinucleina. |
WO2021067761A1 (en) * | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
CN115427443A (zh) | 2020-04-24 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 巯基化合物及其衍生物的酶和途径调节 |
IL300059A (en) * | 2020-07-23 | 2023-03-01 | Othair Prothena Ltd | Anti-Abata antibodies |
CN113912714B (zh) * | 2021-12-15 | 2022-02-22 | 北京凯祥弘康生物科技有限公司 | 特异性结合α-突触核蛋白的抗体及其应用 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AU695129B2 (en) | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
KR100483832B1 (ko) | 1999-02-05 | 2005-04-20 | 삼성전자주식회사 | 영상 텍스쳐 기술자 추출 방법 |
EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
WO2004039234A2 (en) * | 2002-05-13 | 2004-05-13 | Alexion Pharmaceuticals, Inc. | Humanized antibodies against the venezuelan equine encephalitis virus |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
DK1567652T3 (da) | 2002-11-29 | 2007-11-26 | Boehringer Ingelheim Pharma | Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
SI1820022T1 (sl) | 2004-11-10 | 2009-10-31 | Boehringer Ingelheim Pharma | Uporaba pretočne citometrične analize za optimiziranje celičnih bančnih strategij za celice CHO |
US7930064B2 (en) * | 2004-11-19 | 2011-04-19 | Parata Systems, Llc | Automated drug discrimination during dispensing |
US20080300204A1 (en) | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
CA2657681C (en) | 2006-07-14 | 2019-03-19 | Ac Immune S.A. | Humanized antibodies against beta amyloid protein |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
PT2099826E (pt) * | 2007-01-05 | 2014-01-09 | Univ Zuerich | Anticorpo anti-beta-amilóide e suas utilizações |
US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
CA2678963C (en) * | 2007-02-23 | 2018-05-01 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
MY148472A (en) | 2007-03-02 | 2013-04-30 | Boehringer Ingelheim Pharma | Improvement of protein production |
SI2132230T1 (sl) | 2007-03-22 | 2014-07-31 | Genentech, Inc. | Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE |
CA2681743A1 (en) | 2007-03-22 | 2008-09-25 | Imclone Llc | Stable antibody formulations |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
UA101487C2 (en) | 2007-12-21 | 2013-04-10 | Ф. Хоффманн-Ля Рош Аг | Humanized b-ly1 antibody formulation |
AU2008345022B2 (en) | 2007-12-28 | 2014-11-06 | Prothena Biosciences Limited | Treatment and prophylaxis of amyloidosis |
AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
PL2282758T3 (pl) | 2008-04-29 | 2019-04-30 | Bioarctic Ab | Przeciwciała i szczepionki do zastosowania w terapeutycznych i diagnostycznych sposobach dla zaburzeń związanych z alfa-synukleiną |
WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
DE102008048129A1 (de) | 2008-09-20 | 2010-04-22 | Lfk-Lenkflugkörpersysteme Gmbh | Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper |
MX2011006422A (es) | 2008-12-19 | 2011-09-15 | Panima Pharmaceuticals Ag | Autoanticuerpos humanos anti-alfa-sinucleina. |
MX2012001268A (es) | 2009-07-28 | 2012-09-12 | Shire Human Genetic Therapies | Composiciones y metodos para tratar enfermedad de gaucher. |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
EP2519537A4 (en) | 2009-12-29 | 2013-07-10 | Reddys Lab Ltd Dr | CLEANING PROTEINS |
EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
JP6060073B2 (ja) * | 2010-04-08 | 2017-01-11 | ジェイエヌ バイオサイエンシーズ エルエルシー | Cd122に対する抗体 |
MX336540B (es) * | 2010-06-08 | 2016-01-22 | Genentech Inc | Conjugados y anticuerpos manipulados geneticamente con cisteina. |
EP3363499A1 (en) * | 2010-06-11 | 2018-08-22 | Kyowa Hakko Kirin Co., Ltd. | Anti-tim-3 antibody |
LT2593128T (lt) * | 2010-07-15 | 2018-06-25 | Adheron Therapeutics, Inc. | Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai |
JP6023715B2 (ja) | 2010-10-11 | 2016-11-09 | アッヴィ・バハマズ・リミテッド | タンパク質の精製方法 |
CA2825791A1 (en) | 2011-02-07 | 2012-08-16 | Neotope Biosciences Limited | Apoe immunotherapy |
WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
CN103764166B (zh) | 2011-06-22 | 2017-10-24 | 通用医疗公司 | 蛋白质病的治疗 |
CA2835242A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
CN104039826A (zh) | 2011-10-31 | 2014-09-10 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
EP2807188B1 (en) * | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
RS58928B1 (sr) | 2012-08-29 | 2019-08-30 | Hoffmann La Roche | Transporter za krvno-moždanu barijeru |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2013
- 2013-01-25 EP EP13740871.2A patent/EP2807188B1/en active Active
- 2013-01-25 CN CN201380007018.8A patent/CN104619724B/zh not_active Expired - Fee Related
- 2013-01-25 US US13/750,983 patent/US8790644B2/en not_active Expired - Fee Related
- 2013-01-25 RU RU2014134747A patent/RU2642262C2/ru active
- 2013-01-25 KR KR1020207006200A patent/KR102246217B1/ko active IP Right Grant
- 2013-01-25 BR BR112014018561A patent/BR112014018561A8/pt active Search and Examination
- 2013-01-25 UA UAA201409460A patent/UA115439C2/uk unknown
- 2013-01-25 MY MYPI2014002199A patent/MY171140A/en unknown
- 2013-01-25 MX MX2014008952A patent/MX360778B/es active IP Right Grant
- 2013-01-25 WO PCT/US2013/023307 patent/WO2013112945A1/en active Application Filing
- 2013-01-25 CA CA2863953A patent/CA2863953A1/en not_active Abandoned
- 2013-01-25 ES ES13740871T patent/ES2749457T3/es active Active
- 2013-01-25 KR KR1020147024060A patent/KR102086061B1/ko active IP Right Grant
- 2013-01-25 AU AU2013211874A patent/AU2013211874B2/en not_active Ceased
- 2013-01-25 NZ NZ629296A patent/NZ629296A/en not_active IP Right Cessation
- 2013-01-25 CN CN201810297949.0A patent/CN108517010A/zh active Pending
- 2013-01-25 JP JP2014554890A patent/JP6342333B2/ja not_active Expired - Fee Related
- 2013-01-25 SG SG11201404321YA patent/SG11201404321YA/en unknown
- 2013-01-25 DK DK13740871.2T patent/DK2807188T3/da active
- 2013-01-25 IN IN7149DEN2014 patent/IN2014DN07149A/en unknown
-
2014
- 2014-07-24 US US14/340,342 patent/US9234031B2/en not_active Expired - Fee Related
- 2014-07-24 US US14/340,355 patent/US9217030B2/en not_active Expired - Fee Related
- 2014-07-24 PH PH12014501685A patent/PH12014501685A1/en unknown
- 2014-07-24 MX MX2018014044A patent/MX2018014044A/es unknown
- 2014-07-25 CL CL2014001984A patent/CL2014001984A1/es unknown
- 2014-07-27 IL IL233829A patent/IL233829B/en active IP Right Grant
- 2014-08-25 ZA ZA2014/06227A patent/ZA201406227B/en unknown
-
2015
- 2015-06-03 HK HK15105305.2A patent/HK1204791A1/xx unknown
- 2015-11-10 US US14/937,792 patent/US9670273B2/en active Active
-
2017
- 2017-05-04 US US15/587,255 patent/US10118960B2/en not_active Expired - Fee Related
-
2018
- 2018-05-16 JP JP2018094968A patent/JP6807893B2/ja active Active
- 2018-09-27 US US16/144,923 patent/US10597441B2/en not_active Expired - Fee Related
-
2020
- 2020-02-19 US US16/795,479 patent/US10875909B2/en active Active
-
2021
- 2021-03-22 IL IL281731A patent/IL281731A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2807188T3 (da) | Humaniserede antistoffer, der genkender alpha-synuclein | |
HK1212361A1 (en) | Antibodies recognizing alpha synuclein | |
DK3378535T3 (da) | Humanserede antistoffer, der genkender alpha-synuklein | |
DK2934584T3 (da) | Anti-gdf15-antistoffer | |
DK3083694T3 (da) | Caniniserede, murine anti-canin-pd-1-antistoffer | |
HK1217023A1 (zh) | 新型抗體 | |
DK2850101T3 (da) | Anti-FcRn-antistoffer | |
DK2847231T3 (da) | Multispecifikke monoklonale antistoffer | |
CO7020871A2 (es) | Anticuerpos anti-il-36r | |
DK3336106T3 (da) | Anti-fcrh5-antistoffer | |
BR112014024769A2 (pt) | anticorpo humanizado tau | |
DK3156416T3 (da) | Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer | |
CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
DK2817333T3 (da) | Bispecifikke, asymmetriske igg4-antistoffer | |
DK2521736T3 (da) | Humaniserede antistoffer | |
DK3071595T3 (da) | Humaniseret anti-kallikrein-2-antistof | |
DK2825559T3 (da) | Letisolerbare bispecifikke antistoffer med nativt immunoglobulinformat | |
DK3708583T3 (da) | Ikke-fucosylerede anti-fgfr2iiib-antistoffer | |
CR20140127A (es) | Anticuerpo anti-abtcr | |
DE112012002421A5 (de) | Duchführung | |
BR112014025037A2 (pt) | anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente | |
DK2828292T3 (da) | Jcv-neutraliserende antistoffer | |
DK3068800T3 (da) | FcRn-specifikke antistoffer | |
DK3431504T3 (da) | Antiphospholipase d4-antistof | |
DK2931748T3 (da) | Bmp-6-antistoffer |